Skip to main content

Advertisement

SpringerLink
Log in

A cell-based screen for inhibitors of protein folding and degradation

  • Original Paper
  • Published:
Cell Stress and Chaperones Aims and scope

Abstract

Cancer cells are exposed to external and internal stresses by virtue of their unrestrained growth, hostile microenvironment, and increased mutation rate. These stresses impose a burden on protein folding and degradation pathways and suggest a route for therapeutic intervention in cancer. Proteasome and Hsp90 inhibitors are in clinical trials and a 20S proteasome inhibitor, Velcade, is an approved drug. Other points of intervention in the folding and degradation pathway may therefore be of interest. We describe a simple screen for inhibitors of protein synthesis, folding, and proteasomal degradation pathways in this paper. The molecular chaperone-dependent client v-Src was fused to firefly luciferase and expressed in HCT-116 colorectal tumor cells. Both luciferase and protein tyrosine kinase activity were preserved in cells expressing this fusion construct. Exposing these cells to the Hsp90 inhibitor geldanamycin caused a rapid reduction of luciferase and kinase activities and depletion of detergent-soluble v-Src::luciferase fusion protein. Hsp70 knockdown reduced v-Src::luciferase activity and, when combined with geldanamycin, caused a buildup of v-Src::luciferase and ubiquitinated proteins in a detergent-insoluble fraction. Proteasome inhibitors also decreased luciferase activity and caused a buildup of phosphotyrosine-containing proteins in a detergent-insoluble fraction. Protein synthesis inhibitors also reduced luciferase activity, but had less of an effect on phosphotyrosine levels. In contrast, certain histone deacetylase inhibitors increased luciferase and phosphotyrosine activity. A mass screen led to the identification of Hsp90 inhibitors, ubiquitin pathway inhibitors, inhibitors of Hsp70/Hsp40-mediated refolding, and protein synthesis inhibitors. The largest group of compounds identified in the screen increased luciferase activity, and some of these increase v-Src levels and activity. When used in conjunction with appropriate secondary assays, this screen is a powerful cell-based tool for studying compounds that affect protein synthesis, folding, and degradation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

References

  • Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622

    CAS  PubMed  Google Scholar 

  • An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355–360

    CAS  PubMed  Google Scholar 

  • Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729–26734

    Article  CAS  PubMed  Google Scholar 

  • Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM (2001) The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15:1537–1543

    Article  CAS  PubMed  Google Scholar 

  • Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L (2008) 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51:196–218

    Article  CAS  PubMed  Google Scholar 

  • Bruening W, Giasson B, Mushynski W, Durham HD (1998) Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 26:486–489

    Article  CAS  PubMed  Google Scholar 

  • Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31:164–172

    Article  CAS  PubMed  Google Scholar 

  • Chang HC, Nathan DF, Lindquist S (1997) In vivo analysis of the Hsp90 cochaperone Sti1 (p60). Mol Cell Biol 17:318–325

    CAS  PubMed  Google Scholar 

  • Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM (1997) Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A 94:5798–5803

    Article  CAS  PubMed  Google Scholar 

  • Dahlmann B (2005) Proteasomes. Essays Biochem 41:31–48

    Article  CAS  PubMed  Google Scholar 

  • Dey B, Caplan AJ, Boschelli F (1996a) The Ydj1 molecular chaperone facilitates formation of active p60v-src in yeast. Mol Biol Cell 7:91–100

    CAS  PubMed  Google Scholar 

  • Dey B, Lightbody JJ, Boschelli F (1996b) CDC37 is required for p60v-src activity in yeast. Mol Biol Cell 7:1405–1417

    CAS  PubMed  Google Scholar 

  • Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels—proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2:231–238

    Article  CAS  PubMed  Google Scholar 

  • Gould GW, Cuenda A, Thomson FJ, Cohen P (1995) The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochem J 311(Pt 3):735–738

    CAS  PubMed  Google Scholar 

  • Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K (2005) Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65:10536–10544

    Article  CAS  PubMed  Google Scholar 

  • Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, Workman P, Aherne W (2007) A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol Cancer Ther 6:1112–1122

    Article  CAS  PubMed  Google Scholar 

  • Hutchison KA, Brott BK, De Leon JH, Perdew GH, Jove R, Pratt WB (1992) Reconstitution of the multiprotein complex of pp 60src, hsp90, and p50 in a cell-free system. J Biol Chem 267:2902–2908

    CAS  PubMed  Google Scholar 

  • Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, Tashima Y (1999) A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem J 343(Pt 3):697–703

    Article  CAS  PubMed  Google Scholar 

  • Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chene P (2008) NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 10:R33

    Article  PubMed  Google Scholar 

  • Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12:2955–2960

    Article  CAS  PubMed  Google Scholar 

  • Kang Y, Taldone T, Clement CC, Fewell SW, Aguirre J, Brodsky JL, Chiosis G (2008) Design of a fluorescence polarization assay platform for the study of human Hsp70. Bioorg Med Chem Lett 18:3749–3751

    Article  CAS  PubMed  Google Scholar 

  • Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF (2007) Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 50:2767–2778

    Article  CAS  PubMed  Google Scholar 

  • Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G (2004) Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen 9:375–381

    Article  CAS  PubMed  Google Scholar 

  • Kimura Y, Yahara I, Lindquist S (1995) Role of the protein chaperone YDJ1 in establishing Hsp90-mediated signal transduction pathways. Science 268:1362–1365

    Article  CAS  PubMed  Google Scholar 

  • Kimura Y, Rutherford SL, Miyata Y, Yahara I, Freeman BC, Yue L, Morimoto RI, Lindquist S (1997) Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 11:1775–1785

    Article  CAS  PubMed  Google Scholar 

  • Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601–607

    Article  CAS  PubMed  Google Scholar 

  • Lotz GP, Lin H, Harst A, Obermann WM (2003) Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 278:17228–17235

    Article  CAS  PubMed  Google Scholar 

  • Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181–37186

    Article  CAS  PubMed  Google Scholar 

  • McClellan AJ, Tam S, Kaganovich D, Frydman J (2005) Protein quality control: chaperones culling corrupt conformations. Nat Cell Biol 7:736–741

    Article  CAS  PubMed  Google Scholar 

  • McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 66:10967–10975

    Article  CAS  PubMed  Google Scholar 

  • McDonough H, Patterson C (2003) CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 8:303–308

    Article  CAS  PubMed  Google Scholar 

  • Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L (2004) Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 3:551–566

    CAS  PubMed  Google Scholar 

  • Miyata Y (2005) Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11:1131–1138

    Article  CAS  PubMed  Google Scholar 

  • Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB (2005) Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 280:33792–33799

    Article  CAS  PubMed  Google Scholar 

  • Powers MV, Clarke PA, Workman P (2008) Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14:250–262

    Article  CAS  PubMed  Google Scholar 

  • Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K (2008) HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112:1886–1893

    Article  CAS  PubMed  Google Scholar 

  • Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25:151–159

    Article  CAS  PubMed  Google Scholar 

  • Sefton BM, Patschinsky T, Berdot C, Hunter T, Elliott T (1982) Phosphorylation and metabolism of the transforming protein of Rous sarcoma virus. J Virol 41:813–820

    CAS  PubMed  Google Scholar 

  • Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95:323–348

    Article  CAS  PubMed  Google Scholar 

  • Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67:2206–2216

    Article  CAS  PubMed  Google Scholar 

  • Solit DB, Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6:1205–1214

    Article  CAS  PubMed  Google Scholar 

  • Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD (2007) Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 67:10445–10454

    Article  CAS  PubMed  Google Scholar 

  • Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370–374

    Article  CAS  PubMed  Google Scholar 

  • Wendler PA, Boschelli F (1989) Src homology 2 domain deletion mutants of p60v-src do not phosphorylate cellular proteins of 120–150 kDa. Oncogene 4:231–236

    CAS  PubMed  Google Scholar 

  • Westerheide SD, Kawahara TL, Orton K, Morimoto RI (2006) Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 281:9616–9622

    Article  CAS  PubMed  Google Scholar 

  • Williamson DS, Borgognoni J, Clay A, Daniels Z, Dokurno P, Drysdale MJ, Foloppe N, Francis GL, Graham CJ, Howes R, Macias AT, Murray JB, Parsons R, Shaw T, Surgenor AE, Terry L, Wang Y, Wood M, Massey AJ (2009) Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J Med Chem 52:1510–1513

    Article  CAS  PubMed  Google Scholar 

  • Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202–216

    Article  CAS  PubMed  Google Scholar 

  • Wright DD, Sefton BM, Kamps MP (1994) Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 14:2429–2437

    CAS  PubMed  Google Scholar 

  • Xu Y, Lindquist S (1993) Heat-shock protein hsp90 governs the activity of pp 60v-src kinase. Proc Natl Acad Sci U S A 90:7074–7078

    Article  CAS  PubMed  Google Scholar 

  • Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY (2006) Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res 66:1783–1791

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Wyeth Research (now the Center for Integrative Biology and Biotherapeutics, Pfizer R & D), 401 N. Middletown Rd., Pearl River, NY, 10965, USA

    Frank Boschelli, Jennifer M. Golas, Roseann Petersen, Vincent Lau, Lei Chen, Diane Tkach, Qiang Zhao, Dave S. Fruhling, Hao Liu, Chaneun Nam & Kim T. Arndt

Authors
  1. Frank Boschelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer M. Golas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roseann Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diane Tkach
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dave S. Fruhling
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chaneun Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kim T. Arndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Boschelli.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 32.5 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boschelli, F., Golas, J.M., Petersen, R. et al. A cell-based screen for inhibitors of protein folding and degradation. Cell Stress and Chaperones 15, 913–927 (2010). https://doi.org/10.1007/s12192-010-0200-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12192-010-0200-3

Keywords

Search

Navigation